This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Atreca Gelecekteki Büyüme
Future kriter kontrolleri 0/6
Atreca is forecast to grow earnings at 4.3% per annum.
Anahtar bilgiler
4.3%
Kazanç büyüme oranı
n/a
EPS büyüme oranı
Biotechs kazanç büyümesi | 35.6% |
Gelir büyüme oranı | n/a |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | Low |
Son güncelleme | 31 May 2024 |
Gelecekteki son büyüme güncellemeleri
Güncelleme yok
Recent updates
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | N/A | -52 | N/A | N/A | 1 |
12/31/2025 | N/A | -48 | N/A | N/A | 1 |
12/31/2024 | N/A | -38 | N/A | N/A | 1 |
12/31/2023 | N/A | -65 | N/A | N/A | 1 |
9/30/2023 | N/A | -98 | -65 | -65 | N/A |
6/30/2023 | N/A | -85 | -65 | -64 | N/A |
3/31/2023 | N/A | -93 | -71 | -70 | N/A |
12/31/2022 | N/A | -97 | -82 | -81 | N/A |
9/30/2022 | N/A | -105 | -86 | -81 | N/A |
6/30/2022 | N/A | -110 | -88 | -81 | N/A |
3/31/2022 | N/A | -108 | -93 | -69 | N/A |
12/31/2021 | N/A | -109 | -96 | -61 | N/A |
9/30/2021 | N/A | -103 | -96 | -63 | N/A |
6/30/2021 | N/A | -98 | -93 | -62 | N/A |
3/31/2021 | N/A | -92 | -82 | -66 | N/A |
12/31/2020 | N/A | -86 | -72 | -67 | N/A |
9/30/2020 | N/A | -83 | -70 | -65 | N/A |
6/30/2020 | N/A | -76 | -71 | -65 | N/A |
3/31/2020 | N/A | -74 | -67 | -63 | N/A |
12/31/2019 | N/A | -67 | -62 | -59 | N/A |
9/30/2019 | N/A | -59 | -56 | -53 | N/A |
6/30/2019 | N/A | -53 | -47 | -45 | N/A |
3/31/2019 | N/A | -44 | -41 | -40 | N/A |
12/31/2018 | N/A | -38 | -36 | -35 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 0C1 is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: 0C1 is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: 0C1 is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: Insufficient data to determine if 0C1's revenue is forecast to grow faster than the German market.
Yüksek Büyüme Geliri: 0C1 is forecast to have no revenue next year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if 0C1's Return on Equity is forecast to be high in 3 years time